Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by canadafanon Apr 25, 2024 8:01am
188 Views
Post# 36006611

Todays announcement

Todays announcement

Onc announced today upcoming presentation at an annual oncology conference.
they have two posters. One regarding details of anal cancer trail the other? Seems very vague. 

my best guess/ understanding is to discuss the biomarker details.
timeliines are interesting in that the presentation posters will not be available until after the Onc, AGM.
Typically the data is under embargo, by the conference rules.
meaning they won't be able to discuss details, other than to say they will be presenting .
100% speculation on my part. Watch for just after  the conference , yiu will see Onc advancing the Anal cancer arm to phase 3 approval. Similar to the quick advances we saw with the Pancreatic cancer arm.
that option was hinted at previously.
leaving Onc around mid June with 3 FDA approved phase 3 trials regarding the Gobblet studies with Roche.
That being recommended to advance to phase 3 for MBc, pancreatic & anal cancers.
all that is needed is a business development deal,& final trial details to move forward.


 
 

<< Previous
Bullboard Posts
Next >>